GRAY SUSANNAH 4

What Happened

• Susannah Gray, a director of 4D Molecular Therapeutics (FDMT), received a grant of 50,000 derivative securities on June 17, 2026, reported as acquired at $0.00. The filing identifies the award as a stock option grant under the company’s non-employee director compensation program and shows no cash paid at grant.

Key Details

• Transaction date: 2026-06-17; filing date: 2026-06-18 (timely — filed one day after the report date).
• Amount: 50,000 derivative securities (reported acquisition price $0.00).
• Vesting: 1/3 vests on June 17, 2027, then in equal monthly installments thereafter, fully vested on June 17, 2029; the options also vest in full upon a Change in Control (per footnotes).
• Reason: Automatically granted under the company’s non-employee director compensation program (footnote F1).
• Shares owned after transaction: not specified in the provided excerpt of the filing.

Context

• This was an awards/grant transaction (not a purchase or sale) and represents compensation for board service. As a derivative (option) grant, it does not produce immediate proceeds or sales; value depends on future vesting and exercisability. Such director awards are common and routine; the filing gives the vesting timetable and a Change-in-Control acceleration provision.